Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.

Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes / M. G Peters, M. Yuen, N. Terrault, J. Fry, P. Lampertico, E. Gane, C. Hwang, L. M Stamm, M. Leus, M. K Maini, P. Mendez, I. Lonjon-Domanec, T. Berg, S. Wang, P. Mishra, E. Donaldson, S. Buchholz, V. Miller, O. Lenz. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - (2023), pp. ciad506.1-ciad506.8. [Epub ahead of print] [10.1093/cid/ciad506]

Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug Classes

P. Lampertico;
2023

Abstract

Chronic hepatitis B, a major cause of liver disease and cancer, affects >250 million people worldwide. Currently there is no cure, only suppressive therapies. Efforts to develop finite curative hepatitis B virus (HBV) therapies are underway, consisting of combinations of multiple novel agents with or without nucleos(t)ide reverse-transcriptase inhibitors. The HBV Forum convened a webinar in July 2021, along with subsequent working group discussions to address how and when to stop finite therapy for demonstration of sustained off-treatment efficacy and safety responses. Participants included leading experts in academia, clinical practice, pharmaceutical companies, patient representatives, and regulatory agencies. This Viewpoints article outlines areas of consensus within our multistakeholder group for stopping finite therapies in chronic hepatitis B investigational studies, including trial design, patient selection, outcomes, biomarkers, predefined stopping criteria, predefined retreatment criteria, duration of investigational therapies, and follow-up after stopping therapy. Future research of unmet needs are discussed.
Chronic hepatitis B; Functional cure; HBV biomarkers; New combination therapy; Stopping finite therapy
Settore MED/12 - Gastroenterologia
2023
26-ago-2023
Article (author)
File in questo prodotto:
File Dimensione Formato  
ciad506.pdf

accesso aperto

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 377.82 kB
Formato Adobe PDF
377.82 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1001410
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact